Immunology
Congress Materials - ODAC Dermatology 2026
2026 ODAC Dermatology | Jan 16-19 | Orlando, FL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults (Weeks 24-52) and Continuous Treatment in Adolescents (Through Week 52) From the Phase 3, ICONIC-LEAD Trial
Jennifer Soung, Yong Cui, Robert Bissonnette, Mark G. Lebwohl, Álvaro González Cantero, Andreas Pinter, Phoebe Rich, Vimal H. Prajapati, Megan Miller-Kassamali, Joseph Cafone, Gigi Jiang, Shu Li, Kush Shah, Cynthia DeKlotz, Ya-Wen Yang, Andrew E. Pink
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.